Identification, characterization, and engineering of glycosylation in thrombolytics
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079750" target="_blank" >RIV/00159816:_____/23:00079750 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/23:00131494
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0734975023000812?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0734975023000812?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.biotechadv.2023.108174" target="_blank" >10.1016/j.biotechadv.2023.108174</a>
Alternative languages
Result language
angličtina
Original language name
Identification, characterization, and engineering of glycosylation in thrombolytics
Original language description
Cardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and throm-bectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modification in thrombolytic enzymes is a viable strategy for their improvement. This comprehensive review summarizes current knowledge on computational and experimental identification of glycosylation sites and glycan identity, together with methods used for their reengineering. Practical examples from previous studies focus on modification of gly-cosylations in thrombolytics, e.g., alteplase, tenecteplase, reteplase, urokinase, saruplase, and desmoteplase. Collected clinical data on these glycoproteins demonstrate the great potential of this engineering strategy. Outstanding combinatorics originating from multiple glycosylation sites and the vast variety of covalently attached glycan species can be addressed by directed evolution or rational design. Directed evolution pipelines would benefit from more efficient cell-free expression and high-throughput screening assays, while rational design must employ structure prediction by machine learning and in silico characterization by supercomputing. Perspectives on challenges and opportunities for improvement of thrombolytic enzymes by engineering and evolution of protein glycosylation are provided.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biotechnology Advances
ISSN
0734-9750
e-ISSN
1873-1899
Volume of the periodical
66
Issue of the periodical within the volume
SEP 2023
Country of publishing house
GB - UNITED KINGDOM
Number of pages
23
Pages from-to
108174
UT code for WoS article
001009152300001
EID of the result in the Scopus database
—